Clinical trials: Castrate-resistant Prostate Cancer
Prostate Cancer Metastatic
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
This is a first-in-human Phase 1/2, multinational, multicenter, open-label study of HB-302/HB-301 alternating 2-vector therapy in participants with metastatic castration-resistant prostate cancer (mCRPC) comprising 2 phases: a…
- Trial name
- NCT05553639
- Testing
- HB-302/HB-301 Alternating 2-Vector Therapy
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- Hookipa Biotech GmbH
mCRPC (Metastatic Castration-resistant Prostate Cancer), Advanced Malignant Solid Tumor
A Study of MHB048C in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB048C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07192120
- Testing
- MHB048C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
This randomized, placebo-controlled phase III trial is evaluating the benefit of rucaparib and enzalutamide combination therapy versus enzalutamide alone for the treatment of men with prostate cancer that has spread to other…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- CASPAR (NCT04455750)
- Testing
- Enzalutamide, Rucaparib camsylate, Leuprolide Acetate
- Where
- 414 sites in United States
- Volunteers
- 61 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Neoplasms
Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer
This Phase I, open-label, dose-finding, multicenter study is designed to determine the recommended Phase II dose (RP2D) for the combination of an orally administered Phosphatidylinositol-4,5-bisphosphate 3-kinase beta (PI3K-beta)…
- Trial name
- NCT02215096
- Testing
- GSK2636771, Enzalutamide
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline
Prostate Cancer Metastatic to Bone
Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy
Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone.
- Trial name
- RaRe (NCT03458559)
- Testing
- Radium-223 chloride, Rhenium-188-HEDP
- Where
- Netherlands
- Volunteers
- 402 people
- Sponsor
- Amsterdam UMC, location VUmc
Metastatic Castration-resistant Prostate Cancer
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant…
- Trial name
- NCT03732820
- Testing
- olaparib, abiraterone acetate
- Where
- 132 sites in United States, Australia and 15 more
- Volunteers
- 895 people
- Sponsor
- AstraZeneca
Metastatic Castration-Resistant Prostate Cancer
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer
This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.
- Trial name
- ENZA-p (NCT04419402)
- Testing
- Lu-PSMA, Enzalutamide
- Where
- 15 sites in Australia
- Volunteers
- 162 people
- Sponsor
- Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Metastatic Castration-resistant Prostate Cancer
Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)
The SPECTacular study will enroll patients who are already undergoing a FDA approved PSMA-targeted Radioligand treatment cycle. During each treatment cycle, patients will receive 5 additional SPECT/CT scans to investigate the…
- Trial name
- SPECTacular (NCT05823402)
- Testing
- SPECT/CT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BAMF Health
Advanced Solid Tumors, CRPC
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
This is a Phase 1/2, open-label, multi-center, non-randomized, dose-escalation study to be conducted in two parts: the Dose Escalation Phase and the Dose Expansion Phase.
- Conditions
- Advanced Solid Tumors, CRPC, mCRPC, Metastatic Castrate-resistant Prostate Cancer
- Trial name
- NCT02266745
- Testing
- PT-112 Injection
- Where
- 25 sites in United States, France
- Volunteers
- 109 people
- Sponsor
- Promontory Therapeutics Inc.
Prostatic Neoplasms, Prostate Cancer
Fulvestrant in Hormone Refractory Prostate Cancer
The purpose of this study is to determine if treatment with fulvestrant leads to a slowing of tumor progression in patients who have developed androgen-independent (AIPC) or hormone-refractory prostate cancer (HRPC) and who have…
- Trial name
- NCT00476645
- Testing
- Fulvestrant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Prostate Cancer Metastatic Castration-Resistant
External Beam and Radioligand Radiotherapy for mCRPC
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with Lutetium-177 (¹⁷⁷Lu-PSMA) is an established treatment for metastatic prostate cancer.
- Trial name
- ARREST (NCT07354594)
- Testing
- External Beam Radiotherapy Delivered Between Cycles of Radioligand Radiotherapy, Standard of care 177Lutetium-PSMA
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Prostate Cancer Metastatic
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
The purpose of this study is to allow patients similar to that evaluated in the TROPIC trial (NCT00417079), and Investigators access to cabazitaxel for the management of metastatic Hormone Refractory Prostate Cancer (mHRPC) in…
- Trial name
- NCT01254279
- Testing
- CABAZITAXEL
- Where
- 165 sites in Australia, Austria and 27 more
- Volunteers
- 984 people
- Sponsor
- Sanofi
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
This is a Phase 1b/2 study evaluating FOR46 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) after prior progression on abiraterone.
- Trial name
- NCT05011188
- Testing
- FOR46, Enzalutamide, Pegfilgrastim
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Rahul Aggarwal
Metastatic Castration-resistant Prostate Cancer
Study of Enzalutamide in Patients With Castration-resistant Prostate Cancer
This research study is evaluating a drug called enzalutamide in metastatic castration resistant prostate cancer. Enzalutamide is already FDA approved for metastatic castration resistant prostate cancer after treatment with…
- Trial name
- NCT01942837
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC)
YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer
This phase I study tests a personalized cancer vaccine (Neo-DC) for men with advanced prostate cancer (metastatic castration-resistant prostate cancer, or mCRPC) that has continued to grow despite standard hormone therapies and…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer Patients, Castration-Resistant Prostate Cancer (CRPC), Prostate Neoplasms
- Trial name
- YS247 (NCT07583160)
- Testing
- Autologous Neoantigen-Pulsed Dendritic Cell Vaccine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
Prostate Cancer
A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer
The purpose of this study is to determine the safety and effectiveness of the study drug carlumab in participants with metastatic castrate-resistant prostate cancer (cancer of the gland that makes fluid that aids movement of…
- Trial name
- NCT00992186
- Testing
- Carlumab
- Where
- 13 sites in United States, Belgium and 2 more
- Volunteers
- 46 people
- Sponsor
- Centocor Research & Development, Inc.
Prostate Cancer
Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
This study will look to see if the combination of ridaforolimus and bicalutamide works better than placebo and bicalutamide in men with prostate cancer.
- Trial name
- NCT00777959
- Testing
- ridaforolimus (MK8669), open-label ridaforolimus (MK8669)
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA)…
- Trial name
- CATCH-177 (NCT06738303)
- Testing
- Cabazitaxel and carboplatin, Lu-PSMA-617
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer, Castration-Resistant Prostate Cancer
AI Multimodal Model for Predicting CRPC Progression Risk
This study aims to develop an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing castration-resistant prostate cancer (CRPC), a more severe form of the disease.
- Trial name
- AI-MM_CPRC (NCT07658573)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Guangxi Medical University
Metastatic Castration Resistant Prostate Cancer (CRPC)
Phase IIB Clinical Trial of Hamsa-1™ in Metastatic Castration Resistant Prostate Cancer (CRPC)
Hamsa-1™ is an anti-angiogenic drug combination designed for the treatment of cancer. The investigational product Hamsa-1™ comprises of four well-known active components.
- Trial name
- TLH-202 (NCT00684970)
- Testing
- Hamsa-1™ TL-118
- Where
- 5 sites in Israel
- Volunteers
- 100 people
- Sponsor
- Tiltan Pharma Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.